IDEXX Labs CFO Change – Andrew Emerson to Succeed Brian McKeon

By Tamara Parker • Thursday, November 21 10:20 • Permanent Link

IDEXX Laboratories, Inc. (NASDAQ: IDXX) has announced a change in its executive leadership with the retirement of Brian McKeon, the current Chief Financial Officer (CFO), effective June 1, 2025. Andrew Emerson, who is currently serving as the Senior Vice President of Corporate and Companion Animal Group (CAG) Finance, will succeed Mr. McKeon as the company's next CFO, effective March 1, 2025. Mr. McKeon will serve as the Executive Vice President and Special Advisor to the company from March 1, 2025, until his retirement, to ensure a smooth transition.

Since Mr. Emerson’s joining in November 2015, he has led the finance organization for the CAG business and assumed responsibility for the corporate finance function, including investor relations, financial planning and analysis, accounting, tax, and treasury, in March 2020. His nearly 20 years of broad financial experience, along with nine years of deep knowledge of the company's strategy and finances, makes him a natural fit for the CFO role.

Under Mr. McKeon's leadership, the CAG business now generates more than 90% of IDEXX’s total revenue, indicating significant growth for the company. Additionally, Mr. Emerson has overseen corporate finance areas since 2020, contributing to the company's financial reporting, investor relations, tax, treasury, and financial planning and analysis.

IDEXX Laboratories, Inc. also reaffirmed its 2024 full-year guidance as provided on October 31, 2024, demonstrating a commitment to its financial targets despite the upcoming transition in the CFO position.

IDEXX Laboratories, Inc. is a global leader in pet healthcare innovation, with diagnostic and software products and services that support the veterinary community worldwide. The company, headquartered in Maine, employs approximately 11,000 people and offers solutions and products to customers in more than 175 countries and territories. Following these announcements, the company's shares moved -1.1%, and are now trading at a price of $413.91. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.